Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| clinical deterioration | clinical improvement | deaths | viral clearance | |||
| Ad26.RSV.preF (respiratory syncytial virus) | 0 | - | - | - | - | |
| Ad26.ZEBOV () | 0 | - | - | - | - | |
| Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine) | 0 | - | - | - | - | |
| CanSino (Convidecia) | 0 | - | - | - | - | |
| Covishield (Oxford/AZ formulation) | 0 | - | - | - | - | |
| Janssen AD26 vaccine (JNJ-78436735) | 0 | - | - | - | - | |
| Sputnik V (Gam-COVID-Vac) | 0 | - | - | - | - | |
| SPUTNIK-LIGHT | 0 | - | - | - | - | |
| Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) | 0 | - | - | - | - | |
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
